Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211831 · ClinicalTrials.gov registry record · Phase 2
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
A Phase 2 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT04211831 is a Phase 2 study that has completed, run by Urovant Sciences. The registered enrollment target is 80 participants.
The verdict
NCT04211831, a Phase 2 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.
Interventions
- DRUG Placebo
- DRUG URO-902
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2022-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211831
The ClinicalTrials.gov registry entry for NCT04211831 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04211831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04211831 about?
NCT04211831 is a clinical study titled "URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence". This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.
What is the current status of trial NCT04211831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2019-12-16. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT04211831?
The interventions under investigation include: Placebo (DRUG), URO-902 (DRUG).
Who is sponsoring clinical trial NCT04211831?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.